EOLS

In the past six months, Evolus, Inc. (EOLS) stock increased by 81.03%, and by 30.08% between October 1, 2025, and September 30, 2026. The company reported strong financial results for the second quarter of 2026, with 21% year-over-year revenue growth and its third consecutive quarter of positive adjusted EBITDA. Evolus raised its full-year 2026 net revenue guidance to a range of $330 million to $337 million. The company expanded its global injectable portfolio by adding Profhilo, with anticipated U.S. commercialization in 2030, and by expanding the Estyme franchise into Canada, Australia, and New Zealand, with expected commercialization in 2028. Evolus anticipates FDA approval for Evolysse Sculpt, a mid-face volume product, in the fourth quarter of 2026. On October 2, 2026, the U.S. Food and Drug Administration (FDA) issued a warning to Evolus regarding a "false or misleading" Instagram promotional post for Jeuveau, citing potential public health risks due to misrepresentation of the drug's safety and efficacy, specifically objecting to claims suggesting Jeuveau could make frown lines disappear, deliver complete results, and begin working within two days. Insider trading activity in the past three months shows insiders sold approximately $950,176.00 in company stock, with no insider buying reported in the past 12 months. Analysts have set an average target price of $15.00 for EOLS, suggesting a potential upside of approximately 95.06%.